Cantor Fitzgerald Research Analysts Raise Earnings Estimates for Adlai Nortye Ltd. (NASDAQ:ANL)

Adlai Nortye Ltd. (NASDAQ:ANL) – Investment analysts at Cantor Fitzgerald lifted their FY2024 earnings estimates for Adlai Nortye in a research report issued to clients and investors on Tuesday, April 23rd. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings per share of ($2.41) for the year, up from their prior estimate of ($2.50). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Adlai Nortye’s current full-year earnings is ($2.90) per share.

Adlai Nortye Price Performance

ANL opened at $13.55 on Thursday. The company’s 50 day moving average is $9.21 and its 200 day moving average is $9.28. Adlai Nortye has a 12-month low of $7.11 and a 12-month high of $19.30.

Hedge Funds Weigh In On Adlai Nortye

A hedge fund recently raised its stake in Adlai Nortye stock. Cantor Fitzgerald L. P. increased its holdings in Adlai Nortye Ltd. (NASDAQ:ANL) by 128.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 40,310 shares of the company’s stock after buying an additional 22,644 shares during the quarter. Cantor Fitzgerald L. P. owned 0.11% of Adlai Nortye worth $362,000 at the end of the most recent reporting period. 35.21% of the stock is currently owned by institutional investors and hedge funds.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.